Your browser doesn't support javascript.
loading
Immunomodulatory effect of IL-2 induced bone marrow mononuclear cell therapy on control of allergic asthma
Yin, Jingjing; Yan, Fengdi; Zheng, Ruiqiang; Wu, Xiaoyan; Shamsadin Athari, Seyyed.
Afiliação
  • Yin, Jingjing; Subei People’s Hospital. Department of Critical Care Medicine. Yangzhou. China
  • Yan, Fengdi; Subei People’s Hospital. Department of Critical Care Medicine. Yangzhou. China
  • Zheng, Ruiqiang; Subei People’s Hospital. Department of Critical Care Medicine. Yangzhou. China
  • Wu, Xiaoyan; Subei People’s Hospital. Department of Critical Care Medicine. Yangzhou. China
  • Shamsadin Athari, Seyyed; Zanjan University of Medical Sciences. School of Medicine. Department of Immunology. Zanjan. Iran
Allergol. immunopatol ; 51(1): 110-115, ene. 2023. graf, ilus
Artigo em Inglês | IBECS | ID: ibc-214026
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Asthma is a chronic airway disease. Allergic reactions and T helper (h)2 immune response play a key role in asthma occurrence. Cell therapy can control inflammation and remodeling responses in allergic asthma, and cytokines can change this effect. Therefore, in this study, the effect of treated cell therapy with IL-2 to control allergic asthma was studied. Bone marrow cells were extracted and co-cultured with IL-2 and the cells were used via intra-tracheal administration in allergic asthma mice. Levels of IL-4, IL-5, IL-13, Leukotriene B4 and C4, and remodeling factors were measured. At least, a histopathology test of lung tissue was done. Type2 cytokines, leukotrienes, remodeling factors, mucus secretion, goblet cell hyperplasia, peri-bronchial and peri-vascular inflammation were significantly (p˂0.05) decreased by treating with bone marrow-derived mononuclear cells (BMDMCs) and IL-2-BMDMCs. Treatment with IL-2-BMDMCs could significantly decrease IL-13, transforming growth factor (TGF)-β, HP levels, and mucus secretion (p˂0.05) compared to BMDMCs treatment. In this study, BMDMCs and IL-2-BMDMCs therapy could decrease inflammation, allergic, and remodeling factors in allergic asthma. Cell therapy with BMDMCs had a strong and notable effect on the control of allergic asthma pathophysiology when co-cultured and used with IL-2 (AU)
Assuntos


Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Asma / Células da Medula Óssea / Interleucina-2 / Imunomodulação Limite: Animais Idioma: Inglês Revista: Allergol. immunopatol Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Subei People’s Hospital/China / Zanjan University of Medical Sciences/Iran

Texto completo: Disponível Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Asma / Células da Medula Óssea / Interleucina-2 / Imunomodulação Limite: Animais Idioma: Inglês Revista: Allergol. immunopatol Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Subei People’s Hospital/China / Zanjan University of Medical Sciences/Iran
...